Alicia Zhang

Phase 2 study of the bispecific T-cell engager (BiTE) antibody blinatumomab in relapsed/refractory diffuse large B-cell lymphoma

Andreas Viardot, Marie-Elisabeth Goebeler, Svenja Neumann et al. · Blood · 2016 · 366 citations · Full text

Life Sciences, Hematology, Immunology +16

Panitumumab plus radiotherapy versus chemoradiotherapy in patients with unresected, locally advanced squamous-cell carcinoma of the head and neck (CONCERT-2): a randomised, controlled, open-label phase 2 trial

J. Giralt, José Trigo, Sandra Nuyts et al. · The Lancet Oncology · 2015 · 172 citations

Medicine, Oncology, Radiation Oncology +9

Chemoradiotherapy with or without panitumumab in patients with unresected, locally advanced squamous-cell carcinoma of the head and neck (CONCERT-1): a randomised, controlled, open-label phase 2 trial

Michael Henke, A. Fortin, Heikki Minn et al. · The Lancet Oncology · 2015 · 162 citations

Medicine, Oncology, Radiation Oncology +12

Neurologic adverse events in patients with relapsed/refractory acute lymphoblastic leukemia treated with blinatumomab: management and mitigating factors

Anthony S. Stein, Gary J. Schiller, Ramsis Benjamin et al. · Annals of Hematology · 2018 · 104 citations · Full text

Medicine, Oncology, Pharmacotherapy +17

Blinatumomab treatment of older adults with relapsed/refractory B‐precursor acute lymphoblastic leukemia: Results from 2 phase 2 studies

Hagop M. Kantarjian, Anthony S. Stein, Ralf C. Bargou et al. · Cancer · 2016 · 91 citations · Full text

Medicine, Hematology, Oncology +17